Janux Therapeutics
11099 Torrey Pines Rd. Suite 290
La Jolla
CA
92037
United States
Tel: 858-750-4731
Website: http://www.januxrx.com/
Email: hr@januxrx.com
About Janux Therapeutics
At Janux, we are developing unique immunotherapies that have the potential to generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue. We believe that combining Janux’s tumor-specific activation with multi-stage anti-tumor signaling will significantly improve safety, expand the therapeutic dosing window, and maximize patient responses.
8 articles with Janux Therapeutics
-
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
5/10/2022
Janux Therapeutics, Inc., a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, reported financial results for the first quarter ended March 31, 2022 and provided a business update.
-
Several biopharma companies are closing out the month of April with expansions to facilities, including a $3 billion investment to develop next-generation life science ecosystems.
-
Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr
4/26/2022
Janux Therapeutics today announced its upcoming presentation of preclinical data for the Company’s two lead TRACTr programs, PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008).
-
Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
3/18/2022
Janux Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.
-
Janux Therapeutics to Present at Upcoming March Investor Conferences
3/1/2022
Janux Therapeutics, Inc. today announced that Janux management will participate in three upcoming investor conferences.
-
Janux Therapeutics Appoints Byron Robinson, Ph.D., J.D., as Chief Strategy Officer
3/1/2022
Janux Therapeutics, Inc. today announced the appointment of Byron Robinson, Ph.D., J.D., as Chief Strategy Officer.
-
Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference
1/5/2022
Janux Therapeutics, Inc. announced that Janux management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference being held January 10 to 13.
-
Janux Therapeutics to Present Virtually at Upcoming Investor Conferences
11/8/2021
Janux Therapeutics, Inc. today announced that Janux management will participate in fireside chats at two upcoming virtual investor conferences: Cowen’s 5th Annual IO Next Summit